Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2004-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.48.4.1089-1095.2004PMID 15047506PMCID PMC375307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of Bidirectional Cephalexin Transport Across MDCK and Caco-2 Cell Monolayers: Interactions with Peptide Transporters

  2004cited by this paper
• Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].

  2003cited by this paper
• Effect of Tenofovir on Didanosine Absorption in Patients with HIV

  2003cited by this paper
• Metabolism of Tenofovir and Didanosine in Quiescent or Stimulated Human Peripheral Blood Mononuclear Cells

  2003cited by this paper
• Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase*

  2003cited by this paper
• Pancreatitis Treated with Didanosine and Tenofovir Disoproxil Fumarate

  2003cited by this paper
• The boosting of didanosine by allopurinol permits a halving of the didanosine dosage.

  2002cited by this paper
• Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase*

  2001cited by this paper
• Pharmacokinetic and Other Drug Interactions in Patients With AIDS

  2001cited by this paper
• Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers.

  2001cited by this paper
• Purine nucleoside phosphorylases: properties, functions, and clinical aspects.

  2000cited by this paper
• Interactions of calf spleen purine nucleoside phosphorylase with antiviral acyclic nucleoside phosphonate inhibitors: kinetics and emission studies.

  1999cited by this paper
• Antiviral acyclic nucleoside phosphonate analogues as inhibitors of purine nucleoside phosphorylase.

  1998cited by this paper
• Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

  1998cited by this paper
• Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

  1998cited by this paper
• Effect of High‐Dose Oral Ganciclovir on Didanosine Disposition in Human Immunodeficiency Virus (HIV)‐Positive Patients

  1998cited by this paper
• Oral absorption of anti‐ AIDS nucleoside analogues. 3. Regional absorption and in vivo permeability of 2′, 3′ ‐ dideoxyinosine in an intestinal–vascular access port (IVAP) dog model

  1997cited by this paper
• Purine nucleoside phosphorylase. 1. Structure-function studies.

  1997cited by this paper
• Guanine, pyrazolo[3,4-d]pyrimidine, and triazolo[4,5-d]pyrimidine (8-azaguanine) phosphonate acyclic derivatives as inhibitors of purine nucleoside phosphorylase.

  1996cited by this paper
• Guanine, Pyrazolo(3,4-d)pyrimidine, and Triazolo(4,5-d)pyrimidine (8- Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase (PNPase).

  1996cited by this paper
• Discovering High-Affinity Ligands for Proteins: SAR by NMR

  1996cited by this paper
• Oral absorption of anti-AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations.

  1995cited by this paper
• Potentiating effect of (2-[2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl]-phenyl]ethenyl) -phosphonic acid (MDL 74,428), a potent inhibitor of purine nucleoside phosphorylase, on the antiretroviral activities of 2',3'-dideoxyinosine combined with ribavirin in mice.

  1994cited by this paper
• Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors.

  1993cited by this paper
• Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.

  1993cited by this paper
• Metabolism of 2',3'-dideoxyinosine (ddI) in human blood.

  1992cited by this paper
• Pharmacokinetics of 2′, 3′‐dideoxyadenosine and 2′, 3′‐dideoxyinosine in patients with severe human immunodeficiency virus infection

  1990cited by this paper
• Inhibition of human purine nucleoside phosphorylase by acyclic nucleosides and nucleotides.

  1987influential reference
• Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.

  1987influential reference
• Properties of two unusual, and fluorescent, substrates of purine-nucleoside phosphorylase: 7-methylguanosine and 7-methylinosine.

  1986cited by this paper
• Design of purine nucleoside phosphorylase inhibitors.

  1986cited by this paper
• Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

  1986cited by this paper
• Purine Nucleoside Phosphorylase

  1985cited by this paper
• Enzymic determination of inorganic phosphates, organic phosphates and phosphate-liberating enzymes by use of nucleoside phosphorylase-xanthine oxidase (dehydrogenase)-coupled reactions.

  1985cited by this paper
• Effects of acyclovir and its metabolites on purine nucleoside phosphorylase.

  1984influential reference
• Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates.

  1980cited by this paper
• Suppression of cellular immunity due to inhibition of purine nucleoside phosphorylase by allopurinol-riboside.

  1979cited by this paper
• Inhibition of purine nucleoside phosphorylase activity and of T-cell function with allopurinol-riboside

  1979cited by this paper
• Purine nucleoside phosphorylase. Microheterogeneity and comparison of kinetic behavior of the enzyme from several tissues and species.

  1975cited by this paper
• Desoxyribose-1-phosphate. II. The isolation of crystalline desoxyribose-1-phosphate.

  1950cited by this paper

• Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review

  2023cites this paper
• Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection

  2022cites this paper
• Characterising Alzheimer's disease through integrative NMR- and LC-MS-based metabolomics

  2021cites this paper
• Drug Interactions of Non-HIV Antiviral Agents

  2018cites this paper
• Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors

  2018cites this paper
• Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.

  2017cites this paper
• Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.

  2017cites this paper
• Bioanalysis and pharmacokinetics-pharmacodynamics modeling of the endogenous 2'deoxynucleoside triphosphate pool in individuals receiving tenofovir/emtricitabine

  2017influential citation
• The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development.

  2017cites this paper
• Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine

  2016cites this paper
• Clinical Drug-Drug Interaction Data: Effects of Co-administered Drugs on Pharmacokinetics of Antiretroviral Agents

  2016cites this paper
• Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates

  2016cites this paper
• Reduced Immune Activation During Tenofovir–Emtricitabine Therapy in HIV-Negative Individuals

  2015cites this paper
• Developing safer HIV drugs : elucidating the mechanistic pathway of Tenofovir-induced cytotoxicity via mitochondrial dysfunction

  2014cites this paper
• The role of drug transporters in the kidney: lessons from tenofovir

  2014cites this paper
• Amiodarone and Concurrent Antiretroviral Therapy: A Case Report and Review of the Literature

  2014cites this paper
• The Frequency of Adjusted Renal Dosing of Tenofovir DF and Its Effects on Patient Outcomes

  2013cites this paper
• Insights into Phosphate Cooperativity and Influence of Substrate Modifications on Binding and Catalysis of Hexameric Purine Nucleoside Phosphorylases

  2012cites this paper
• Use of antineoplastic agents in cancer patients with HIV/AIDS

  2012cites this paper
• Tenofovir Disoproxil Fumarate

  2012cites this paper
• Didanosine Enteric-Coated Capsule

  2012influential citation
• Chapter 11 – Overview of antiretroviral therapy

  2012cites this paper
• Antiretrovirals for HIV Exposure Prophylaxis.

  2012cites this paper
• Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

  2012cites this paper
• Tenofovir: Once-daily Dosage in the Management of HIV Infection:

  2012cites this paper
• N-phosphonocarbonylpyrrolidine derivatives of guanine: a new class of bi-substrate inhibitors of human purine nucleoside phosphorylase.

  2012cites this paper
• Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides

  2012cites this paper
• Structure-activity-resistance relationships of novel nucleoside and nucleotide HIV-1 reverse transcriptase inhibitors

  2012cites this paper
• Chapter 13 – Pharmacology of antiretroviral drugs

  2012cites this paper
• Mitochondrial functionalism in HIV-infected children receiving antiretroviral therapy

  2012cites this paper
• [Clinical relevance of drug interactions].

  2011cites this paper
• The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.

  2011cites this paper
• Some inhibitors of purine nucleoside phosphorylase

  2011cites this paper
• Non-HIV Antiviral Agents

  2011cites this paper
• Effect of Nucleoside and Nucleotide Analog Reverse Transcriptase Inhibitors on Cell-Mediated Immune Functions

  2011cites this paper
• Intracellular Nucleotide Levels during Coadministration of Tenofovir Disoproxil Fumarate and Didanosine in HIV-1-Infected Patients

  2011cites this paper
• Critical appraisal and update on tenofovir in management of human immunodeficiency virus infection

  2011cites this paper
• Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

  2011cites this paper
• Renal toxicity associated with tenofovir use

  2010cites this paper
• Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients

  2010influential citation
• Inhibition of human purine nucleoside phosphorylase by tenofovir phosphate congeners

  2010cites this paper
• Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

  2010cites this paper
• Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

  2010cites this paper
• Conserved T cell and natural killer cell function in treatment‐experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone

  2009cites this paper
• Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir

  2009influential citation
• Safety and Efficacy of Didanosine Enteric-Coated Capsule in Patients with HIV-1 Infection

  2009cites this paper
• Lopinavir-Ritonavir Abacavir , Lamivudine , or Intracellular Interactions between TDF and ( TDF ) : Investigation of Systemic and Receiving Tenofovir Disoproxil Fumarate Immunodeficiency Virus-Infected Patients Pilot Pharmacokinetic Study of Human

  2009influential citation
• Pharmacogenetics of tenofovir treatment.

  2009cites this paper
• Metabolism of Antiviral Nucleosides and Nucleotides

  2009cites this paper
• HIV INFECTIONS AND AIDS

  2009cites this paper
• A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.

  2008cites this paper
• Current clinical treatments of AIDS.

  2008cites this paper
• Effect of Nucleoside and Nucleotide Reverse Transcriptase Inhibitors of HIV on Endogenous Nucleotide Pools

  2008cites this paper
• Role of multidrug resistance associated proteins in drug development.

  2008cites this paper
• Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens

  2008cites this paper
• Pharmacology of Antiretroviral Drugs

  2008cites this paper
• The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.

  2008cites this paper
• Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition

  2008cites this paper
• Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens

  2008cites this paper
• Clinical Manual of Drug Interaction Principles for Medical Practice

  2008cites this paper
• Mitochondrial Toxicity of Tenofovir, Emtricitabine and Abacavir Alone and in Combination with Additional Nucleoside Reverse Transcriptase Inhibitors

  2007cites this paper
• Why do patients fail HIV therapy?

  2007cites this paper
• Intracellular Metabolism of the Nucleotide Prodrug GS-9131, a Potent Anti-Human Immunodeficiency Virus Agent

  2007cites this paper
• Early Monitoring of Ribavirin Serum Concentration is not Useful to Optimize Hepatitis C Virus treatment in HIV-Coinfected Patients

  2007cites this paper
• Evidence and Possible Consequences of the Phosphorylation of Nucleoside Reverse Transcriptase Inhibitors in Human Red Blood Cells

  2007cites this paper
• Drug interactions in the management of HIV infection: an update

  2007cites this paper
• Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica

  2007cites this paper
• Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.

  2007cites this paper
• Does Tenofovir Influence Efavirenz Pharmacokinetics?

  2007cites this paper
• Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, Nucleotide, and Non-Nucleoside Reverse Transcriptase Inhibitors

  2007cites this paper
• Tratamiento de la hepatitis crónica C en pacientes coinfectados por VIH

  2007cites this paper
• Tenofovir-induced kidney injury

  2007cites this paper
• CD4+ Cell Count Decline Despite HIV Suppression: A Probable Didanosine–Valganciclovir Interaction

  2007cites this paper
• Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs.

  2007cites this paper
• Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2'-deoxyadenosine triphosphate by ion-pairing LC/MS/MS.

  2007cites this paper
• Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review.

  2007cites this paper
• [Approach to evaluating the clinical relevance of drug interactions in HIV-infected patients].

  2007cites this paper
• Renal Function in Antiretroviral-Experienced Patients treated with Tenofovir Disoproxil Fumarate associated with Atazanavir/ritonavir

  2007cites this paper
• Inhibition of MRP 1 / ABCC 1 , MRP 2 / ABCC 2 , and MRP 3 / ABCC 3 by Nucleoside , Nucleotide , and Non-Nucleoside Reverse Transcriptase Inhibitors

  2007cites this paper
• The first once-daily single-tablet regimen for the treatment of HIV-infected patients.

  2007cites this paper
• Response to Blaas et al., 'Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases'.

  2007cites this paper
• Clinically Stable Treatment-Experienced Adults Receiving Tenofovir and Didanosine

  2006cites this paper
• In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells

  2006influential citation
• Tenofovir disoproxil fumarate for the treatment of HIV infection

  2006cites this paper
• Low perforin and elevated SHIP-1 expression is associated with functional anergy of natural killer cells in chronic HIV-1 infection

  2006cites this paper
• Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients

  2006cites this paper
• Limitations of current antiretroviral agents and opportunities for development.

  2006cites this paper
• Longitudinal Study on Mitochondrial Effects of Didanosine–Tenofovir Combination

  2006cites this paper
• Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals.

  2006cites this paper
• Absence of Clinically Relevant Pharmacokinetic Interaction Between Ribavirin and Tenofovir in Healthy Subjects

  2006cites this paper
• Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.

  2006cites this paper
• Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy

  2006cites this paper
• High serum urate in HIV-infected persons: the choice of the antiretroviral drug matters

  2006cites this paper
• Mechanism of Active Renal Tubular Efflux of Tenofovir

  2006cites this paper
• Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.

  2006cites this paper
• Initiation of antiretroviral therapy

  2006cites this paper
• [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].

  2006cites this paper
• [Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].

  2006cites this paper
• Efectividad inmunológica de las combinaciones de análogos de nucleósidos/nucleótidos, tenofovir + lamivudina, didanosina + lamivudina y tenofovir + didanosina, en pacientes con infección por el VIH y supresión virológica mantenida

  2006cites this paper
• Stavudine, Didanosine, and Zalcitabine

  2006cites this paper